- Home
- » Tags
- » Albiglutide
Top View
- An Overview of GLP-1 Agonists and Recent Cardiovascular Outcomes Trials Kelsey H Sheahan ,1 Elizabeth a Wahlberg,2 Matthew P Gilbert1
- A Meta-Analysis Comparing Clinical Effects of Short
- New Drug Evaluation: Albiglutide Month/Year of Review: January
- Clinical Review Hyon Kwon, Pharmd, MPH Snda 208751/S-010 and S-011 Fiasp (Insulin Aspart)
- Therapeutic Class Overview Therapeuticincretin Mimeticsclass Overview & Amylinomimetics
- Insulin Degludec/Liraglutide (Ideglira) for the Treatment of Type 2 Diabetes
- Semaglutide Subcutaneous Once-Weekly
- Albiglutide (TANZEUM) Drug Monograph
- Glucagon Like Peptide 1 Receptor Agonists: a Therapy for Diabetes
- The Place of Ideglira in the Management of Patients with Type 2 Diabetes
- Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
- Safety of Semaglutide
- Albiglutide (Tanzeum) FDA in April, 2014, for Adjunct Treatment of Diabetes Mel- Diabetes Mellitus Is an Expensive Disease in the United States Litus
- Reappraising the Role of the Vagus Nerve in GLP‐1‐Mediated
- (EMDAC) June 20, 2017
- Albiglutide Eperzan® for Type 2 Diabetes Mellitus Drug Assessment Report No Weight Loss, No Use DTB Navarre
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists a Review of Their Efficacy and Tolerability
- 208471Orig1s000
- Abiglutide and Dulaglutide New Medicine Review
- Albiglutide (Tanzeum) for Diabetes Mellitus
- Incretin Mimetics & Amylinomimetics
- Insulin Pocketcard™ Years Action Insulin Name Onset Peak Effective Considerations Duration
- Diabetes Medications Timeline of Insulin Therapies in the US
- GIP As a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
- Lipid Management in Patients with Endocrine Disorders
- Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
- GLP-1 Agonists
- Risk Assessment and Risk Mitigation Review(S)
- Systematic Review and Meta-Analysis for Prevention of Cardiovascular
- Once-Weekly GLP-1 Receptor Agonists for the Management Of
- MEDICATION GUIDE TANZEUM (TAN-Zee-Um) (Albiglutide)
- Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St
- Albiglutide) for Injection, for Subcutaneous Use Reaction to Albiglutide Or Any of the Product Components
- Pharmacologically Relevant Drug Interactions of Glucagon-Like Peptide-1 Receptor Agonists
- The Regulation of Appetite by Gut Hormones
- Once-Daily Liraglutide Versus Lixisenatide As Add-On to Metformin
- Tanzeum (Albiglutide) Injection Due to Limited Prescribing of the Medicine
- Finger Prickin' Good: New Drugs ‐ Injectables
- Injectable Antidiabetic Agents Policy #: Rx.01.162
- Assessing the Association Between GLP-1 Receptor Agonist Use And